Drug Profile
Research programme: ECM protein modulators - 3B Pharmaceuticals
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator 3B Pharmaceuticals
- Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Extracellular matrix protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Solid-tumours in Germany
- 28 Feb 2018 No recent reports of development identified for research development in Solid-tumours(Diagnosis) in Germany
- 13 Jan 2014 Early research in Solid tumours (diagnosis) in Germany (unspecified route)